Sydney-based NanoGel, a company co-founded by ex-CSIRO scientists Dr Minoo Moghaddam and Dr Maxine McCall, has joined the Advanced Manufacturing Growth Centre (AMGC) as its 3,000th member.
Founded in late-2019, NanoGel is an Australian company that manufactures skin-delivered products for pain relief, cancer treatment, and skin rejuvenation.
Dr Moghaddam, director at NanoGel, said the company is currently working in collaboration with two Sydney-based SMEs, that will each incorporate a NanoGel formulation into a topical cream.
She said the first product is a “naturally-occurring, active pain-relief ingredient in a nanostructured gel.”
“We have trialed this product with many people and their feedback was extremely positive, in fact they all encouraged us to get it to market as soon as possible,” Dr Moghaddam added.
“We are using our background in nano-science to develop and better deliver active ingredients through skin to reduce pain, treat skin cancers, and revitalise skin.”
Dr McCall, a former leader of CSIRO’s nanosafety research program, said the company is in the process of attaining regulatory approval for its first product.
“We are seeking TGA approval for the active ingredient as well as the end product,” Dr McCall said.
“Our timeline is dependent on us attaining financial support to complete the regulatory process. Once approval is obtained, we can move quickly to production.”
Dr Jens Goennemann, Managing Director, AMGC, said the not-for-profit organisation was excited to welcome NanoGel as its 3,000th member.
“What a fantastic example of what manufacturing can be: driven by brains and fueled by world-class Australian research and development,” Dr Goennemann said.
“NanoGel is delivering new-to-world solutions with global relevance and with significant commercial potential.”
